DelveInsight Blog
Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.
From Wrist to Wellness: The Evolving Landscape of Wearable Medical Devices Market
The healthcare market has witnessed a remarkable transformation in recent years, largely driven by rapid advancements in technology and innovation. Among the most notable developments is the evolution of wearable medical devices, which have transcended their traditional roles to become indispensable tools in the modern healthcare ecosystem. This evolution is not only attributable to technological advancements but also to the growing awareness and demand for personalized, accessible, and proactive healthcare solutions. Wearable medical devices such as wristbands, headbands, earwear, and watches, among others, have garnered significant importance owing to their…
X4 Pharmaceuticals’ XOLREMDI FDA Approval; ONO to Acquire Deciphera Pharmaceuticals; Johnson & Johnson’s SIRTURO CHMP Approval; BeiGene’s Tislelizumab EC Approval; Sanofi’s Rilzabrutinib LUNA 3 Phase III Trial
FDA Greenlights XOLREMDI Capsules from X4 Pharmaceuticals for WHIM Syndrome Treatment X4 Pharmaceuticals has declared that the FDA has granted approval for XOLREMDI™ (mavorixafor) capsules to be utilized in individuals aged 12 and above who have WHIM syndrome (characterized by warts, hypogammaglobulinemia, infections, and myelokathexis). This approval aims to enhance the count of mature neutrophils and lymphocytes circulating in the bloodstream. XOLREMDI, an inhibitor of the selective CXC chemokine receptor 4 (CXCR4), represents a breakthrough in treating WHIM syndrome, a rare disorder combining primary immunodeficiency and chronic neutropenia due to…
Breaking Boundaries: Innovations and Updates in Schizophrenia Treatment
Key Highlights INVEGA and VRAYLAR (US)/REAGILA (EU) (cariprazine) accounted for the major share of the revenue market for schizophrenia patients in 2023. However, according to DelveInsight, this share is expected to decline by 2034 due to the launch of new emerging therapies. Schizophrenia has a robust drug development pipeline, which targets glycine transporter, D-amino acid oxidase (DAAO) inhibitor, or other neurotransmitter systems involved in schizophrenia that are expected to influence market dynamics. A few potential emerging schizophrenia therapies such as Boehringer Ingelheim’s Iclepertin (BI-425809), Sumitomo Pharma America/Otsuka Pharmaceutical’s Ulotaront (SEP-363856),…
-Agonist.png "Toll-like Receptors Agonist")
